Is EPO therapy able to correct iron deficiency anaemia caused by matriptase-2 deficiency?

British Journal of Haematology

Volumn 152, Issue 4, 2011, Pages 498-500

  Nicolas, Gaël ^a,b   Deschemin, Jean Christophe ^a,b   Ramsay, Andrew J ^c   Mayeux, Patrick ^a,b   Grandchamp, Bernard ^b,d   Beaumont, Carole ^b   Velasco, Gloria ^c   Vaulont, Sophie ^a,b  

^a INSTITUT COCHIN   (France)

^b INSERM   (France)

^c DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^d BICHAT HOSPITAL   (France)

Author keywords

Anaemia; Erythropoietin; Hepcidin; Hormone; Iron; Matriptase 2

Indexed keywords

HEMOGLOBIN; HEPCIDIN; MATRIPTASE 2; RECOMBINANT ERYTHROPOIETIN; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; ENZYME DEFICIENCY; ERYTHROPOIESIS; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; IRON DEFICIENCY ANEMIA; LETTER; MATRIPTASE 2 DEFICIENCY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANEMIA, IRON-DEFICIENCY; ANIMALS; ERYTHROPOIETIN, RECOMBINANT; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; SERINE ENDOPEPTIDASES;

EID: 78851471634     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08473.x     Document Type: Letter

References (11)

1. Ashby, D.R., Gale, D.P., Busbridge, M., Murphy, K.G., Duncan, N.D., Cairns, T.D., Taube, D.H., Bloom, S.R., Tam, F.W., Chapman, R., Maxwell, P.H. & Choi, P. (2010) Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica, 95, 505-508.
2. Babitt, J.L., Huang, F.W., Wrighting, D.M., Xia, Y., Sidis, Y., Samad, T.A., Campagna, J.A., Chung, R.T., Schneyer, A.L., Woolf, C.J., Andrews, N.C. & Lin, H.Y. (2006) Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nature Genetics, 38, 531-539.
3. Du, X., She, E., Gelbart, T., Truksa, J., Lee, P., Xia, Y., Khovananth, K., Mudd, S., Mann, N., Moresco, E.M., Beutler, E. & Beutler, B. (2008) The serine protease TMPRSS6 is required to sense iron deficiency. Science, 320, 1088-1092.
4. Finberg, K.E. (2009) Iron-refractory iron deficiency anemia. Seminars in Hematology, 46, 378-386.
5. Fishbane, S., Mittal, S.K. & Maesaka, J.K. (1999) Beneficial effects of iron therapy in renal failure patients on hemodialysis. Kidney International Supplement, 69, S67-S70.
6. Folgueras, A.R., de Lara, F.M., Pendas, A.M., Garabaya, C., Rodriguez, F., Astudillo, A., Bernal, T., Cabanillas, R., Lopez-Otin, C. & Velasco, G. (2008) Membrane-bound serine protease matriptase-2 (Tmprss6) is an essential regulator of iron homeostasis. Blood, 112, 2539-2545.
7. Nicolas, G., Chauvet, C., Viatte, L., Danan, J.L., Bigard, X., Devaux, I., Beaumont, C., Kahn, A. & Vaulont, S. (2002) The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. Journal of Clinical Investigation, 110, 1037-1044.
8. Peng, H., Truksa, J. & Lee, P. (2010) EPO-mediated reduction in Hamp expression in vivo corrects iron deficiency anaemia in TMPRSS6 deficiency. British Journal of Haematology, 151, 106-109.
9. Ramsay, A.J., Hooper, J.D., Folgueras, A.R., Velasco, G. & Lopez-Otin, C. (2009) Matriptase-2 (TMPRSS6): a proteolytic regulator of iron homeostasis. Haematologica, 94, 840-849.
10. Silvestri, L., Pagani, A., Nai, A., De Domenico, I., Kaplan, J. & Camaschella, C. (2008) The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metabolism, 8, 502-511.
11. Viatte, L. & Vaulont, S. (2009) Hepcidin, the iron watcher. Biochimie, 91, 1223-1228.